Aldeyra Therapeutics, Inc. - ROE
ALDX
Price:
$1.96
Market Cap:
$118.23M
Aldeyra Therapeutics, Inc. is a biotechnology company focused on the discovery and commercialization of therapeutic agents for ocular and systemic immune-mediated disorders. The firm's primary investigational compound is reproxalap, a reactive aldehyde species (RASP) modulator, currently in Phase III clinical trials for addressing dry eye disease and allergic conjunctivitis. Additionally, Aldeyra is advancing ADX-629, an innovative, first-in-class RASP modulator designed for oral administration, which is undergoing Phase II studies for conditions such as psoriasis, asthma, and COVID-19. Another pipeline asset, ADX-2191, a dihydrofolate reductase inhibitor, is in Phase 3 for the prevention of...[Read more]
Industry
Biotechnology
IPO Date
2014-05-02
Stock Exchange
NASDAQ
Ticker
ALDX
PE Ratio
[-4.36]
ROE
[-57.34%]
Current Ratio
[2.72]
Dividend Yield
[0%]
Enterprise Value
[68.74M]
Dividend History
The ROE as of June 2026 (TTM) for Aldeyra Therapeutics, Inc. (ALDX) is -57.34%
According to Aldeyra Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -57.34%. This represents a change of 309.03% compared to the average of -14.02% of the last 4 quarters.
Aldeyra Therapeutics, Inc. (ALDX) Historical ROE (quarterly & annually)
How has ALDX ROE performed in the past?
The mean historical ROE of Aldeyra Therapeutics, Inc. over the last ten years is -63.29%. The current -57.34% ROE has changed -9.41% with respect to the historical average. Over the past ten years (40 quarters), ALDX's ROE was at its highest in in the December 2023 quarter at -3.97%. The ROE was at its lowest in in the September 2018 quarter at -37.81%.
Average
-63.29%
Median
-59.76%
Minimum
-126.51%
Maximum
-28.08%
Aldeyra Therapeutics, Inc. (ALDX) ROE by Quarter and Year
Discovering the peaks and valleys of Aldeyra Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 181.74%
Maximum Annual ROE = -28.08%
Minimum Annual Increase = -55.50%
Minimum Annual ROE = -126.51%
| Year | ROE | Change |
|---|---|---|
| 2025 | -76.49% | -2.76% |
| 2024 | -78.66% | 150.99% |
| 2023 | -31.34% | -23.70% |
| 2022 | -41.07% | 46.26% |
| 2021 | -28.08% | -55.50% |
| 2020 | -63.11% | -50.12% |
| 2019 | -126.51% | 181.74% |
| 2018 | -44.90% | -20.41% |
| 2017 | -56.42% | -34.68% |
| 2016 | -86.37% | 77.73% |
Aldeyra Therapeutics, Inc. (ALDX) Average ROE
How has ALDX ROE performed in the past?
The current ROE of Aldeyra Therapeutics, Inc. (ALDX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-62.16%
5-year avg
-51.13%
10-year avg
-63.29%
Aldeyra Therapeutics, Inc. (ALDX) ROE vs. Peers
How is ALDX’s ROE compared to its peers?
Aldeyra Therapeutics, Inc.’s ROE is greater than AC Immune S.A. (-123.98%), greater than Mereo BioPharma Group plc (-81.25%), greater than Silence Therapeutics plc (-121.71%), greater than Cellectis S.A. (-80.61%), greater than Genelux Corporation (-165.18%), greater than Contineum Therapeutics, Inc. Class A Common Stock (-27.09%), greater than Alto Neuroscience, Inc. (-47.22%), greater than Amarin Corporation plc (-7.34%), greater than Candel Therapeutics, Inc. (-60.42%), greater than Kyverna Therapeutics, Inc. (-81.87%),
| Company | ROE | Market cap |
|---|---|---|
| -123.98% | $244.26M | |
| -81.25% | $49.39M | |
| -121.71% | $327.33M | |
| -80.61% | $299.24M | |
| -165.18% | $111.53M | |
| -27.09% | $446.39M | |
| -47.22% | $798.04M | |
| -7.34% | $331.54M | |
| -60.42% | $456.23M | |
| -81.87% | $353.40M |
Build a custom stock screener for Aldeyra Therapeutics, Inc. (ALDX) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Aldeyra Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Aldeyra Therapeutics, Inc. (ALDX) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Aldeyra Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Aldeyra Therapeutics, Inc.'s ROE?
How is the ROE calculated for Aldeyra Therapeutics, Inc. (ALDX)?
What is the highest ROE for Aldeyra Therapeutics, Inc. (ALDX)?
What is the 3-year average ROE for Aldeyra Therapeutics, Inc. (ALDX)?
What is the 5-year average ROE for Aldeyra Therapeutics, Inc. (ALDX)?
How does the current ROE for Aldeyra Therapeutics, Inc. (ALDX) compare to its historical average?